Beijing Tiantan Biological Products Corp Ltd (600161) — Cash Flow-to-Debt Ratio
Beijing Tiantan Biological Products Corp Ltd (600161) has a Cash Flow-to-Debt Ratio of 0.20x as of September 2025, meaning its operating cash flow of CN¥318.80 Million could theoretically repay 0% of its total liabilities (CN¥1.60 Billion) in one year. Explore 600161 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing Tiantan Biological Products Corp Ltd Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for Beijing Tiantan Biological Products Corp Ltd across 27 annual periods. Also explore total assets of Beijing Tiantan Biological Products Corp for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Beijing Tiantan Biological Products Corp Ltd (1998–2024)
Year-by-year debt coverage analysis for Beijing Tiantan Biological Products Corp Ltd. For market capitalisation and broader financial context, see 600161 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.61x | CN¥819.78 Million | CN¥1.34 Billion | ▼ -63.3% |
| 2023 | 1.67x | CN¥2.39 Billion | CN¥1.43 Billion | ▲ +134.9% |
| 2022 | 0.71x | CN¥1.13 Billion | CN¥1.58 Billion | ▼ -5.0% |
| 2021 | 0.75x | CN¥980.35 Million | CN¥1.31 Billion | ▲ +60.9% |
| 2020 | 0.46x | CN¥702.11 Million | CN¥1.51 Billion | ▼ -17.7% |
| 2019 | 0.57x | CN¥642.47 Million | CN¥1.14 Billion | ▼ -40.0% |
| 2018 | 0.94x | CN¥677.92 Million | CN¥720.19 Million | ▲ +107.5% |
| 2017 | 0.45x | CN¥218.39 Million | CN¥481.46 Million | ▲ +253.9% |
| 2016 | 0.13x | CN¥428.37 Million | CN¥3.34 Billion | ▼ -8.0% |
| 2015 | 0.14x | CN¥473.26 Million | CN¥3.40 Billion | ▲ +10.7% |
| 2014 | 0.13x | CN¥477.95 Million | CN¥3.80 Billion | ▼ -23.2% |
| 2013 | 0.16x | CN¥566.43 Million | CN¥3.46 Billion | ▲ +14.8% |
| 2012 | 0.14x | CN¥432.00 Million | CN¥3.03 Billion | ▼ -28.2% |
| 2011 | 0.20x | CN¥353.15 Million | CN¥1.78 Billion | ▲ +40.3% |
| 2010 | 0.14x | CN¥184.85 Million | CN¥1.31 Billion | ▼ -61.7% |
| 2009 | 0.37x | CN¥448.23 Million | CN¥1.21 Billion | ▼ -41.2% |
| 2008 | 0.63x | CN¥276.39 Million | CN¥439.35 Million | ▲ +51.3% |
| 2007 | 0.42x | CN¥153.55 Million | CN¥369.34 Million | ▼ -4.1% |
| 2006 | 0.43x | CN¥154.36 Million | CN¥356.20 Million | ▼ -40.9% |
| 2005 | 0.73x | CN¥131.69 Million | CN¥179.67 Million | ▼ -16.3% |
| 2004 | 0.88x | CN¥110.11 Million | CN¥125.70 Million | ▲ +121.7% |
| 2003 | 0.40x | CN¥62.93 Million | CN¥159.24 Million | ▲ +1.0% |
| 2002 | 0.39x | CN¥84.38 Million | CN¥215.73 Million | ▲ +46.1% |
| 2001 | 0.27x | CN¥46.49 Million | CN¥173.64 Million | ▼ -6.8% |
| 2000 | 0.29x | CN¥47.90 Million | CN¥166.77 Million | ▲ +7.8% |
| 1999 | 0.27x | CN¥42.58 Million | CN¥159.88 Million | ▲ +26.4% |
| 1998 | 0.21x | CN¥23.71 Million | CN¥112.54 Million | — |